Uncategorized
Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3
Elicio Therapeutics’ investigational cancer immunotherapy failed to meet the primary endpoint of disease-free survival in a Phase 2 trial—a result the company attributed mostly to a disproportionate number of patients with higher residual disease.